ArticleBMC infectious diseases2026
Comparison of two MALDI-TOF MS platforms for identification of Trichosporon isolates from patients in a tertiary hospital in Hefei, China.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTrichosporon species are emerging opportunistic fungal pathogens associated with nosocomial infections, particularly in immunocompromised individuals. Accurate species identification and antifungal susceptibility testing are essential for appropriate clinical management. However, data on the distribution of Trichosporon species, the identification accuracy of matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF MS), and local epidemiological patterns in Hefei, China, remain limited.
methodsDemographic and clinical data from 99 patients corresponding to 164 Trichosporon isolates collected between June 2019 and December 2024 were retrospectively reviewed to assess epidemiological characteristics. A total of 68 isolates were further analyzed by intergenic spacer 1 (IGS1) sequencing, followed by phylogenetic analysis of the IGS1 region. Species identification was subsequently performed using two MALDI-TOF MS platforms: bioMérieux VITEK-MS and DL Smart MS 5020. Colony morphology was assessed after culture, and in vitro antifungal susceptibility profiles were determined.
resultsA total of 164 Trichosporon isolates from 99 patients were analyzed, with urine as the predominant specimen source (76.83%). Among 34 infected patients, urine remained the most common source (52.94%). These patients were predominantly male (70.59%), immunocompromised (73.53%), aged > 45 years (82.35%), and had undergone recent invasive procedures (82.35%). The median hospital stay was 36.5 days, suggesting that a substantial proportion of infections may have been nosocomial. Colony morphology varied with culture medium and incubation time and was insufficient for reliable species-level identification. Compared with IGS1 sequencing (n = 68), both MALDI-TOF MS platforms showed high genus-level accuracy; at the species level, performance was comparable for Trichosporon asahii (T. asahii) but diverged for Trichosporon asteroides (T. asteroides). Antifungal susceptibility testing revealed generally low minimum inhibitory concentrations (MICs) for amphotericin B (AMB) and triazoles.
conclusionTrichosporon isolates were mainly recovered from urine, particularly from male and immunocompromised patients. MALDI-TOF MS showed high accuracy at the genus level, whereas species-level discrepancies were observed, especially for closely related species such as T. asteroides. These findings suggest that confirmation by IGS1 sequencing, together with antifungal susceptibility testing, may improve species identification and support clinical management. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.